Abiomed

Rodman & Renshaw is downgrading shares of Abiomed, Inc. (NASDAQ: ABMD) from Market Perform to Market Underperform.

Piper Jaffray released its report today on Abiomed (NASDAQ: ABMD) following ABMD's decision to terminate their Protect II Study. In its report, Piper Jaffray writes, "Following the recommendation of its Data Safety Monitoring Board (DSMB), management opted to terminate PROTECT II due to futility....